Arlico Pharm

CompanySouth Korea

Arlico Pharm develops one asset, in human trials (Lithoderm PDRN Repair Cream in skin barrier dysfunction). Mostly other; based in South Korea.

1
Asset
Furthest stage: Human trials; 0
Trials: 1
Signal

Pipeline

1

Lithoderm PDRN Repair Cream
Combines purple gromwell-derived PDRN, exosomes, and extract to support skin barrier function and hydration.
Human trials, Other, skin barrier dysfunction

Full company profiles: pipeline, trials, funding and people.

In the full profile

Signals1